ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "ARIAD Pharmaceuticals, Inc." (ARIA) Report Updated: Dec 05, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"ARIAD Pharmaceuticals, Inc." (ARIA)

Rating: Strong Buy Volatility: Aggressive
Total Grade: A Industry: Biotechnology
Competitors: ALBO,MNOV,VNDA,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: A down no change
Last Week: A same no change
Two Weeks Ago: A up upgrade
service keys

"ARIAD Pharmaceuticals, Inc."© quotemedia

Company Profile

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.